HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial

Hsu JL, Hung MC (2016) The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev 35(4):575–588. https://doi.org/10.1007/s10555-016-9649-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137. https://doi.org/10.1038/35052073

Article  CAS  PubMed  Google Scholar 

Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748. https://doi.org/10.1155/2014/852748

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E (2001) HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12(Suppl 1):S15–19. https://doi.org/10.1093/annonc/12.suppl_1.s15

Article  PubMed  Google Scholar 

Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33–48. https://doi.org/10.1038/s41571-019-0268-3

Article  CAS  PubMed  Google Scholar 

Clifton GT, Peoples AGE (2021) Immunotherapy as a partner for HER2-directed therapies. Expert Rev Anticancer Ther 21(7):739–746. https://doi.org/10.1080/14737140.2021.1894932

Article  CAS  PubMed  Google Scholar 

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98. https://doi.org/10.1200/JCO.2008.19.9844

Article  CAS  PubMed  Google Scholar 

Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, Vahidian F, Gholamiyan Moghadam A, Aghadoukht A, Hajiasgharzadeh K, Baradaran B (2020) Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol 235(4):3142–3156. https://doi.org/10.1002/jcp.29216

Article  CAS  PubMed  Google Scholar 

Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F (2019) Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol 139:53–66. https://doi.org/10.1016/j.critrevonc.2019.05.001

Article  PubMed  Google Scholar 

Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E (2022) Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2 + metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 33(3):321–329. https://doi.org/10.1016/j.annonc.2021.12.005

Article  CAS  PubMed  Google Scholar 

Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J, Group CS (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. https://doi.org/10.1056/NEJMoa1413513

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 2 (2022) (December 20, 2021). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed 06 May 2022

Ulrich L, Okines AFC (2021) Treating advanced unresectable or metastatic HER2-positive breast cancer: a spotlight on tucatinib. Breast Cancer 13:361–381. https://doi.org/10.2147/BCTT.S268451

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2017) ; https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 13 May 2022

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

Article  CAS  PubMed  Google Scholar 

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60. https://doi.org/10.1055/s-0030-1247132

Article  CAS  PubMed  Google Scholar 

Sivagnanam K, Rahman ZU, Paul T (2016) Cardiomyopathy associated with targeted therapy for breast cancer. Am J Med Sci 351(2):194–199. https://doi.org/10.1016/j.amjms.2015.11.014

Article  PubMed  Google Scholar 

HERCEPTIN® (trastuzumab) intravenous infusion [prescribing information] (2010). Genentech, Inc., South San Francisco, CA

PERJETA® (pertuzumab) injection, for intravenous use [prescribing information]Genentech, Inc., South San Francisco, CA

KADCYLA® (ado- (2019) Trastuzumab emtansine) for injection, for intravenous use [prescribing information]. Genentech, Inc., South San Francisco, CA

Google Scholar 

ENHERTU® (fam-trastuzumab (2021) deruxtecan-nxki) for injection, for intravenous use [prescribing information]. Daiichi Sankyo, Inc., Basking Ridge, NJ

Google Scholar 

Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23(6):1275–1284. https://doi.org/10.1007/s11095-006-0205-x

Article  CAS  PubMed  Google Scholar 

Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B (2019) Population pharmacokinetic and covariate analyses of intravenous trastuzumab (herceptin((R))), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. Cancer Chemother Pharmacol 83(2):329–340. https://doi.org/10.1007/s00280-018-3728-z

Article  CAS  PubMed  Google Scholar 

Carney WP, Bernhardt D, Jasani B (2013) Circulating HER2 extracellular domain: a specific and quantitative biomarker of prognostic value in all breast cancer patients? Biomark Cancer 5:31–39. https://doi.org/10.4137/BIC.S12389

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petersen ER, Sorensen PD, Jakobsen EH, Madsen JS, Brandslund I (2013) Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer. Clin Chem Lab Med 51(7):1483–1492. https://doi.org/10.1515/cclm-2012-0558

Article  CAS  PubMed  Google Scholar 

Zhang P, Xiao J, Ruan Y, Zhang Z, Zhang X (2020) Monitoring value of serum HER2 as a predictive biomarker in patients with metastatic breast cancer. Cancer Manag Res 12:4667–4675. https://doi.org/10.2147/CMAR.S254897

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leyland-Jones B, Smith BR (2011) Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 12(3):286–295. https://doi.org/10.1016/S1470-2045(10)70297-7

Article  CAS  PubMed  Google Scholar 

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

Article  CAS  PubMed  Google Scholar 

Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F (2019) EORTC-1203-GITCG - the “INNOVATION”-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group. BMC Cancer 19(1):494. https://doi.org/10.1186/s12885-019-5675-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofheinz RD, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, Margareta Siegler G, Ebert MP, Goekkurt E, Welslau M, Mahlberg O, Homann N, Pink D, Bechstein WO, Reichardt P, Gaiser T, Sookthai D, Pauligk C, Goetze TO, Al-Batran SE (2020) Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 38:450

Article  Google Scholar 

Chung HC, Bang YJ, C SF, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY (2021) First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 17(5):491–501. https://doi.org/10.2217/fon-2020-0737

Article  CAS  PubMed  Google Scholar 

留言 (0)

沒有登入
gif